BACKGROUND:Diabetic patients present with an accelerated atherosclerotic process and an increased risk for future cardiovascular events. In addition to the risk imposed by the disease itself, pharmacological treatment adds also a sizable risk, especially if certain classes of antidiabetic drugs are employed. Animal evidence indicates that dipeptidyl peptidase-4 inhibitors have anti-atherosclerotic effects, yet clinical data are scarcely available. DESIGN: We plan to prospectively investigate the effects of dipeptidyl peptidase-4 inhibition with vildagliptin on a number of atherothrombotic markers and adipokines in patients with proven atherosclerosis and type 2 diabetes. The selected markers are: interleukin-6, high sensitivity C reactive protein, interleukin 1-beta, total adiponectin levels, matrix metallo-proteinase 9 and platelet reactivity testing. Sixty eligible patients will be randomized in a 2:1 ratio to vildagliptin/metformin or metformin only treatment, for a 3-month duration treatment. Blood sampling for the proposed investigations will be taken at enrollment and immediately after completion of the study period. DISCUSSION: Demonstrating antiatherothrombotic properties of dipeptidyl peptidase-4 inhibitors on proven markers is of substantial clinical significance. Coupled with their proven good safety profile these findings could translate into a significant clinical benefit.
RCT Entities:
BACKGROUND:Diabeticpatients present with an accelerated atherosclerotic process and an increased risk for future cardiovascular events. In addition to the risk imposed by the disease itself, pharmacological treatment adds also a sizable risk, especially if certain classes of antidiabetic drugs are employed. Animal evidence indicates that dipeptidyl peptidase-4 inhibitors have anti-atherosclerotic effects, yet clinical data are scarcely available. DESIGN: We plan to prospectively investigate the effects of dipeptidyl peptidase-4 inhibition with vildagliptin on a number of atherothrombotic markers and adipokines in patients with proven atherosclerosis and type 2 diabetes. The selected markers are: interleukin-6, high sensitivity C reactive protein, interleukin 1-beta, total adiponectin levels, matrix metallo-proteinase 9 and platelet reactivity testing. Sixty eligible patients will be randomized in a 2:1 ratio to vildagliptin/metformin or metformin only treatment, for a 3-month duration treatment. Blood sampling for the proposed investigations will be taken at enrollment and immediately after completion of the study period. DISCUSSION: Demonstrating antiatherothrombotic properties of dipeptidyl peptidase-4 inhibitors on proven markers is of substantial clinical significance. Coupled with their proven good safety profile these findings could translate into a significant clinical benefit.
Authors: Yehuda Handelsman; Jeffrey I Mechanick; Lawrence Blonde; George Grunberger; Zachary T Bloomgarden; George A Bray; Samuel Dagogo-Jack; Jaime A Davidson; Daniel Einhorn; Om Ganda; Alan J Garber; Irl B Hirsch; Edward S Horton; Faramarz Ismail-Beigi; Paul S Jellinger; Kenneth L Jones; Lois Jovanovič; Harold Lebovitz; Philip Levy; Etie S Moghissi; Eric A Orzeck; Aaron I Vinik; Kathleen L Wyne Journal: Endocr Pract Date: 2011 Mar-Apr Impact factor: 3.443
Authors: Éva Csongrádi; Béla Nagy; Tibor Fulop; Zsuzsa Varga; Zsolt Karányi; Mária T Magyar; László Oláh; Mária Papp; Andrea Facskó; János Kappelmayer; György Paragh; Miklós Káplár Journal: Thromb Haemost Date: 2011-08-25 Impact factor: 5.249
Authors: U Rauch; J I Osende; J H Chesebro; V Fuster; D A Vorchheimer; K Harris; P Harris; D A Sandler; J T Fallon; S Jayaraman; J J Badimon Journal: Atherosclerosis Date: 2000-11 Impact factor: 5.162
Authors: G Derosa; P Maffioli; I Ferrari; R Mereu; P D Ragonesi; F Querci; I G Franzetti; G Gadaleta; L Ciccarelli; M N Piccinni; A D'Angelo; S A T Salvadeo Journal: Horm Metab Res Date: 2010-06-17 Impact factor: 2.936
Authors: Maria Luz Muzzio; Veronica Miksztowicz; Fernando Brites; Daniel Aguilar; Esteban Martin Repetto; Regina Wikinski; Marcelo Tavella; Laura Schreier; Gabriela Alicia Berg Journal: Arch Med Res Date: 2009-01 Impact factor: 2.235
Authors: Arwa Younis; Dana Eskenazi; Ronen Goldkorn; Jonathan Leor; Nili Naftali-Shani; Enrique Z Fisman; Alexander Tenenbaum; Ilan Goldenberg; Robert Klempfner Journal: Cardiovasc Diabetol Date: 2017-05-22 Impact factor: 9.951